This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anderson, T. J. Articles by Charbonneau, F. Search for Related Content PubMed PubMed Citation Articles by Anderson, T. J. Articles by Charbonneau, F.

Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study)

Todd J. Anderson, MD^*, Eleanor Elstein, MD, BSc, Harry Haber, MPH and François Charbonneau, MD, MSc

^* Cardiovascular Division, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
McGill University, Montreal, Quebec, Canada
Parke-Davis, Ann Arbor, Michigan, USA

View larger version (17K): [in a new window]   Figure 1 A, The absolute change in percent FMD following therapy compares with pretreatment baseline values. Only quinapril resulted in a significant improvement in brachial flow-mediated vasodilation (*p < 0.02). B, The absolute change in the ratio of percent FMD/nitroglycerin-induced vasodilation following therapy compared with baseline values. Again only quinapril resulted in significant improvement (*p = 0.03).

View larger version (17K): [in a new window]   Figure 2 The absolute change in percent FMD following therapy compares with pretreatment baseline values for quinapril and enalapril based on ACE genotype. Significant improvement in FMD seen only in the quinapril group for the ID and II genotype (*p = 0.03).